

NANOFORM FINLAND PLC'S CHANGE NEGOTIATIONS HAVE ENDED

Nanoform Finland Plc | Company Release | February 05, 2026 at 08:05:00 EET

Helsinki, Finland – Nanoform Finland Plc's ("Nanoform") change negotiations initiated on 12 January 2026 have ended. The negotiations were started to optimize and reorganize operations, increase the company's productivity and competitiveness and execute Nanoform's 2030 midterm targets announced at Capital Markets Day December 16th, 2025 (www.nanoform.com/en/inside-information-nanoform-announces-new-midterm-business-targets-for-2030/). The negotiations concerned all personnel that are employed in Finland.

As a result of the negotiations, 49 employees will be made redundant. In addition, temporary part-time layoffs for some of the remaining personnel in Finland starting from 1 March 2026 can be implemented. The duration of these layoffs can be up to 6 months. Through these measures, the company expects to achieve approximately 5–6 million euros in cost savings for calendar year 2026.

"We thank the negotiators for conducting the negotiations in a professional and efficient way. By implementing the decided cost-saving measures, Nanoform is better prepared to execute the first part of our Strategy "Breach the Wall in two places" and to achieve the midterm business targets for 2030", says Edward Hæggström, Nanoform's CEO.

For further information, please contact:

Edward Hæggström, CEO
edward.haeggstrom@nanoform.com

For investor relations queries, please contact:

Henri von Haartman, Director of Investor Relations
hvh@nanoform.com
+46 7686 650 11

About Nanoform

Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 8 588 685 70, certifiedadviser@dnbcarnegie.se. For more information, please visit www.nanoform.com.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform's strategy, business plans and focus. The words "may", "will", "could", "would", "should", "expect", "plan", "anticipate", "intend", "believe", "estimate", "predict", "project", "potential", "continue", "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform's business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks described in the Report of the Board of Directors and Financial Statements for the year ended December 31, 2024 as well as our other past disclosures. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Nanoform's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Attachments

[**Nanoform Finland Plc's change negotiations have ended**](#)